Amycretin: The Oral Amylin/GLP-1 Combo Explained

The Holy Grail: Dual-Action in a Pill

Amycretin represents what many consider the ultimate goal in obesity drug development: combining the proven benefits of multiple hormone pathways into a single oral medication. If successful, amycretin would deliver CagriSema-level efficacy (potentially 20%+ weight loss) without requiring injections — a combination that could transform obesity treatment globally.

The molecule itself is a single peptide engineered to activate both amylin receptors and GLP-1 receptors. Rather than mixing two separate drugs (as CagriSema does), amycretin is designed from the molecular level to interact with both receptor systems. This elegant approach simplifies manufacturing and may offer pharmacokinetic advantages. Combined with Novo Nordisk's proprietary SNAC oral absorption technology, the goal is to deliver this dual-action peptide as a daily pill.

Why the Amylin Pathway Matters

Amylin is a hormone co-secreted with insulin by pancreatic beta cells after meals. In a healthy metabolism, amylin provides important post-meal signals:

• Satiety signaling: Amylin acts on the area postrema in the brainstem to produce feelings of fullness after eating.
• Gastric emptying: Like GLP-1, amylin slows the rate at which food leaves the stomach, extending feelings of fullness.
• Glucagon suppression: Amylin reduces inappropriate glucagon secretion after meals, helping maintain stable blood sugar.
• Distinct brain pathways: Critically, amylin activates appetite-suppressing neurons in areas of the brain that are different from those targeted by GLP-1. This means the two hormones provide additive appetite suppression rather than redundant signaling.

In obese individuals, amylin signaling is often dysfunctional, contributing to excessive appetite and poor meal-related satiety. Restoring robust amylin signaling alongside GLP-1 activation creates a more complete correction of the hormonal imbalances that drive overeating. Learn about current GLP-1 treatment options.

Early Clinical Data

It is important to note that early-phase results can be optimistic due to smaller sample sizes and patient selection. Phase 2 and Phase 3 trials with larger, more diverse populations will provide a more accurate picture of real-world efficacy. The weight loss trajectory may also flatten over time, as occurs with all obesity medications.

Side effects in early trials were consistent with the GLP-1 class: nausea, vomiting, and diarrhea were most common. The severity and frequency will be better characterized in larger studies. Novo Nordisk is optimizing the titration schedule to minimize GI side effects during the dose escalation period.

Amycretin vs Other Pipeline Drugs

What to Watch For

As amycretin progresses through clinical development, key milestones to watch include:

• Phase 2 full results: Complete data from larger, longer Phase 2 studies will reveal whether the impressive early weight loss trajectory is sustained.
• Phase 3 trial initiation: The design and endpoints of Phase 3 trials will signal Novo Nordisk's confidence and regulatory strategy.
• Head-to-head comparisons: Any data comparing amycretin to CagriSema or other competitors would be highly informative.
• Tolerability data: Whether the dual mechanism creates more or different side effects than GLP-1 alone is an important safety question.
• Manufacturing scale-up: Oral peptide manufacturing at the scale needed for a global obesity treatment is a significant challenge that could affect availability timelines.

Frequently Asked Questions